Press "Enter" to skip to content

Newron delays schizophrenia drug trial after FDA raises concerns

Newron must delay a trial of its prospective schizophrenia medicine evenamide after the U.S. Food and Drug Administration raised concerns about central nervous system (CNS) events that have emerged in rats and dogs.

Original source:

Also Read:   Unichem Labs gets USFDA nod to market Allopurinol tablets